Mitoxantrone reduced disability in Iranian patients with multiple sclerosis

Archives of Iranian Medicine

Volumn 10, Issue 1, 2007, Pages 59-64

  Hamzehloo, Ali ^a,b   Etemadifar, Masood ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Mitoxantrone; Multiple sclerosis (MS)

Indexed keywords

MITOXANTRONE;

ADOLESCENT; ADULT; ALOPECIA; AMENORRHEA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRAN; LEUKOPENIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; NAUSEA; PATIENT COMPLIANCE; PHYSICAL DISABILITY; RECURRENCE RISK; RELAPSE; REMISSION; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; ANALGESICS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; IRAN; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33846688280     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Whetten-Goldstein K, Sloan F, Duke University. Reported by Nicholas LaRocca, Director. Health Care Delivery and Policy Research for the National Multiple Sclerosis. Bultine. May 19, 1998.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agent in Multiple Sclerosis. Neurology. 1996; 46: 907-911.
3. Ebers G, Natural history of multiple sclerosis. In: Comston A, Ebers G, Lassmann H, McDonald WI, Matthews B, Wekerle H, eds. McAlpine's Multiple Sclerosis. 3rd ed. London: Churchill Livingstone; 1998: 191-222.
4. Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol. 2003; 23: 133-146.
5. Goodin DS, Frohman EM, Garmany GP Jr. Disease-modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002; 58: 169-178.
6. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003; 61: 1332-1338.
7. Rizvi SA, Howard Z, Edward F. Mitoxantrone for multiple sclerosis in clinical practice. Neurology. 2004; 63 (suppl 6): S25-S27.
8. Jeffery DR, Herndon R. Review of mitoxantrone in the treatment of multiple sclerosis. Neurology. 2004; 63(suppl 6): S19-S24.
9. Neuhaus O, Kiesier BC, Hartung HP. Mechanism of mitoxantrone in multiple sclerosis - what is known? J Neurol Sci. 2004; 223: 25-27.
10. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs. 2004; 18: 379-396.
11. Jain KK. Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin Investig Drugs. 2000; 9: 1139-1149.
12. Edan G, Miller D, Clanet M. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicenter study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997; 62: 112-118.
13. Touchette DR, Durgin TL, Wanke LA, Goodkin DE. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin Ther. 2003; 25: 611-634.
14. Gonsette RE. Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci. 2003; 206: 203-208.
15. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33: 1444-1452.
16. McDonald WR, Compton A, Edan G. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple sclerosis. Ann Neurol. 2001; 50: 121-127.
17. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci. 1992; 242: 96-102.
18. Edan G, Morrissey S, Le Page E. Rational for the use of mitoxantrone in multiple sclerosis. J Neurol Sci. 2004; 223: 35-39.
19. Cursiefen S, Flacheneckcr, Rieckmann P, Toyka KV. Mitoxantrone (Novantrone) in therapy of severe multiple sclerosis. A retrospective study of 15 patients. Nervenarzt. 1999; 70: 723-731.
20. Chaudhuri A, Behan PO. Mitoxantrone trial in multiple sclerosis. Lancet. 2003; 361: 1133-1134.
21. Noseworthy JH, Hopkins M8, Vandervoort MK, Karlik SJ, Lee DH, Penman M, et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology. 1993; 43: 1401-1406.
22. Hartung HP, Gonsette R, König N. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial. Lancet. 2002; 360: 2018-2025.
23. DeCastro S, Cartoni D, Millefiorni E. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol. 1995; 35: 627-632.
24. Strotmann JM, Spindler M, Weilbach FX. Myocardial function in patients with multiple. sclerosis treated with low-doge mitoxantrone. Am J Cardiol. 2002; 89: 1222-1225.
25. Mather FJ, Simon RM, Clark GM, Von Hoff DD. Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies, Cancer Treat Rep. 1987; 71: 609-613.
26. Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology. 2002; 59: 909-913.
27. Edan G, Brochet B, Clanet M. Safety profiles of mitoxantrone in a cohort of 800 multiple sclerosis patients. Mult Scler. 2001; 7: S14.